Modified Nucleoside, Nucleotide, And Nucleic Acid Compositions

Patent No. EP2791160 (titled "Modified Nucleoside, Nucleotide, And Nucleic Acid Compositions") was filed by Moderna on Dec 14, 2012. The application was issued on Mar 2, 2022.

Patent Summary

This pharmaceutical composition comprises a 1-methyl-pseudouridine-modified messenger RNA (mRNA) encoding a polypeptide of interest, formulated as a lipid nanoparticle (LNP). The modification is designed to reduce immunogenicity, minimize innate immune responses (such as cytokine and interferon production), and enhance protein production efficiency and nucleic acid stability compared to unmodified mRNA. The LNP delivery agent may include PEG, cholesterol, cationic lipids, or fusogenic lipids, and may be further encapsulated in polymers, hydrogels, or surgical sealants for controlled or sustained release. The modified mRNA may further incorporate specific 5' and 3' untranslated regions (UTRs), 5' terminal caps (e.g., Cap1), and poly-A tails to optimize tissue-specific expression and intracellular stability.

Patent Family

Patent family tree
Statuses, jurisdictions and citation links are shared on request.

Patent Oppositions (10)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

EP2791160

MODERNA
Application Number
EP12858350A
Filing Date
Dec 14, 2012
Status
Revoked
Apr 18, 2025
Publication Date
Mar 2, 2022